資料載入中.....
|
請使用永久網址來引用或連結此文件:
http://ir.cmu.edu.tw/ir/handle/310903500/29748
|
| 題名: | Tc-99m MIBI liver imaging for hepatocellular carcinoma: Correlation with P-glycoprotein-multidrug-resistance gene expression |
| 作者: | Chang, CS;Yang, SS;Yeh, HZ;Kao, CH;Chen, GH |
| 貢獻者: | 附設醫院核子醫學部;Taichung Vet Gen Hosp, Div Gastroenterol, Taichung, Taiwan;Chung Shan Med Univ, Dept Internal Med, Taichung, Taiwan;China Med Coll Hosp, Dept Nucl Med, Taichung, Taiwan;Natl Young Min Med Univ, Dept Internal Med, Taipei, Taiwan |
| 日期: | 2004 |
| 上傳時間: | 2010-09-24 14:41:46 (UTC+8) |
| 出版者: | H G E UPDATE MEDICAL PUBLISHING S A |
| 摘要: | Background: Hypofunction of N-methyl-D-aspartate glutamate receptor bad been implicated in the pathophysiology of schizophrenia. Treatment with D-serine or glycine, endogenous full agonists of the glycine site of N-methyl-D-aspartate receptor, or D-cycloserine, a partial agonist, improve the symptoms of schizophrenia. N-methylglycine (sarcosine) is an endogenous antagonist of glycine transporter-1, which potentiates glycine's action on N-methyl-D-aspartate glycine site and can have beneficial effects on schizophrenia. Methods: Thirty-eight schizophrenic patients were enrolled in a 6-week double-blind, placebo-controlled trial of sarcosine (2 g/d), which was added to their stable antipsychotic regimens. Twenty of them received risperidone. Measures of clinical efficacy and side effects were determined every other week. Results: Patient who received sarcosine treatment revealed significant improvements in their positive, negative, cognitive, and general psychiatric symptoms. Similar therapeutic effects were observed when only risperidone-treated patients were analyzed. Sarcosine was well-tolerated, and no significant side effect was noted. Conclusions: Sarcosine treatment can benefit schizophrenic patients treated by antipsychotics including risperidone. The significant improvement with the sarcosine further supports the hypothesis of N-methyl-D-aspartate receptor hypofunction in schizophrenia. Glycine transporter-1 is a novel target for the pharmacotherapy to enhance N-methyl-D-aspartate function. |
| 關聯: | HEPATO-GASTROENTEROLOGY 51(55):211-214 |
| 顯示於類別: | [台中附設醫院] 期刊論文
|
在CMUR中所有的資料項目都受到原著作權保護.
|
